-
Aldeyra Therapeutics Inc. NASDAQ:ALDX Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.
Location: | Website: www.aldeyra.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
252.6M
Cash
80.33M
Avg Qtr Burn
-7.68M
Short % of Float
6.91%
Insider Ownership
2.45%
Institutional Own.
60.20%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Reproxalap Details Dry eye syndrome | NDA Acceptance for review | |
ADX-2191 (methotrexate injection (DHFR inhibitor)) Details Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma | NDA FDA meeting | |
Reproxalap (ADX-102) Details Rare genetic disease, Rare diseases, Allergic conjunctivitis | Phase 3 Update | |
ADX-2191 (methotrexate injection (DHFR inhibitor)) Details Eye disease , Retinitis Pigmentosa | Phase 2/3 Initiation | |
ADX-629 Details Sjögren-Larsson Syndrome | Phase 2 Data readout | |
ADX-629 Details Alcoholic hepatitis, Liver disease | Phase 2 Data readout | |
ADX-629 Details Chronic cough | Phase 2 Update | |
ADX-629 Details Idiopathic Nephrotic Syndrome | Phase 2a Data readout | |
ADX-629 Details Atopic dermatitis | Phase 2a Update | |
ADX-246 Details Atopic dermatitis, Skin disease/disorder | Phase 1/2 Data readout | |
ADX-248 Details Age-related macular degeneration, Geographic atrophy | Phase 1/2 Initiation | |
ADX-248 Details Atopic dermatitis, Skin disease/disorder | Phase 1 Initiation |